---
title: "Bio Medica Laboratories Ltd (BMLL) — Share Price, Financials & Analysis"
symbol: "BMLL"
company: "Bio Medica Laboratories Ltd"
canonical: "https://tapetide.com/stocks/BMLL"
isin: "INE1BKA01015"
nse_symbol: "BMLL"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 197.43
generated_at: "2026-09-13T18:47:51.909Z"
---

# Bio Medica Laboratories Ltd (BMLL)

Canonical page: https://tapetide.com/stocks/BMLL

## Company

- **NSE Symbol:** BMLL
- **ISIN:** INE1BKA01015
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Listed Since:** 2026-05-29
- **Face Value:** ₹10
- **F&O Eligible:** No

## About

Incorporated in August 2015, 
Bio Medica Laboratories Ltd 
specialises in manufacturing 
pharmaceutical parenteral 
formulations, producing a 
wide range of ethical drugs, 
generic drugs, and over-the
-counter (OTC) medications[1]

## Latest Price

- **Price:** ₹158
- **Change:** -2 (-1.25%)
- **Open:** ₹158
- **Day High:** ₹158
- **Day Low:** ₹157
- **Previous Close:** ₹160
- **Volume:** 5000
- **As Of:** 2026-09-11T07:05:31+00:00

## Key Fundamentals

Observed at 2026-09-11T04:48:44.321326Z.

- **Market Cap:** ₹197.43 Cr
- **Classification:** SME
- **P/E (reported):** 16.9
- **Book Value:** ₹58.61
- **Price to Book:** 2.73
- **Dividend Yield:** 0%
- **ROE:** 66.48%
- **ROCE:** 64.81%
- **Debt to Equity:** 1.54
- **Revenue (yearly):** ₹38.3 Cr
- **Net Income:** ₹11.56 Cr
- **EBITDA:** ₹18.38 Cr
- **52-Week High:** ₹181
- **52-Week Low:** ₹101.5
- **RSI (14):** 55

## Growth Rates

| Metric | 1Y | 3Y | 5Y |
| --- | --- | --- | --- |
| cash flow growth | -326.54% | -260.26% | -113.82% |
| ebitda margin growth | 19.49% | 28.16% | — |
| net income growth | 17.96% | 362.4% | — |
| revenue growth | 0% | 35.78% | — |
| roce | 82.15% | 290.89% | — |
| roe | 31.38% | 43.58% | — |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2026 |
| --- | --- |
| Sales | 43 |
| Expenses | 23 |
| Operating Profit | 20 |
| OPM % | 46 |
| Other Income | 0 |
| Interest | 2 |
| Depreciation | 1 |
| Profit before tax | 16 |
| Tax % | 27 |
| Net Profit | 12 |
| EPS in Rs | 13.06 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2026 |
| --- | --- |
| Sales | 43 |
| Expenses | 23 |
| Operating Profit | 20 |
| OPM % | 46 |
| Other Income | 0 |
| Interest | 2 |
| Depreciation | 1 |
| Profit before tax | 16 |
| Tax % | 27 |
| Net Profit | 12 |
| EPS in Rs | 13.06 |
| Dividend Payout % | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2026 |
| --- | --- |
| Equity Capital | 9 |
| Reserves | 17 |
| Borrowings | 40 |
| Other Liabilities | 7 |
| Total Liabilities | 73 |
| Fixed Assets | 17 |
| CWIP | 0 |
| Investments | 0 |
| Other Assets | 56 |
| Total Assets | 73 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2026 |
| --- | --- |
| Cash from Operating Activity | -6 |
| Cash from Investing Activity | -2 |
| Cash from Financing Activity | 8 |
| Net Cash Flow | 0 |
| Free Cash Flow | -8 |
| CFO/OP | -9 |

### Ratios

| Item | Mar 2026 |
| --- | --- |
| Debtor Days | 92 |
| Inventory Days | 759 |
| Days Payable | 116 |
| Cash Conversion Cycle | 735 |
| Working Capital Days | 300 |

## Shareholding Pattern

### Quarterly

| Category | Aug 2025 | May 2026 |
| --- | --- | --- |
| Promoters | 100% | 67.7% |
| FIIs | 0% | 0.29% |
| DIIs | 0% | 2.31% |
| Government | 0% | 0% |
| Public | 0% | 21.38% |
| Others | 0% | 8.33% |
| No. of Shareholders | 0 | 1195 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Buy
- **Buy / Neutral / Sell:** 6 / 10 / 3

### Moving Averages — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 159.5 | Sell |
| EMA (10) | 159.32 | Sell |
| SMA (20) | 156.42 | Buy |
| EMA (20) | 156.57 | Buy |
| SMA (50) | 148.07 | Buy |
| EMA (50) | 148.45 | Buy |
| SMA (100) | — | Neutral |
| EMA (100) | — | Neutral |
| SMA (200) | — | Neutral |
| EMA (200) | — | Neutral |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 53.1 | Neutral |
| MACD (12,26,9) | 3.83 | Sell |
| Stochastic (14,3,3) | 39.73 | Neutral |
| ADX (14) | 33.48 | Buy |
| Williams %R (14) | -64.43 | Neutral |
| ATR (14) | 6.93 | High Volatility |
| ROC (12) | 3 | Buy |
| Stoch RSI (14) | 27.29 | Neutral |
| UO (7,14,28) | 44.98 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 7 Sep - 11th AGM on 28 September 2026 at 2:00 PM via VC/OAVM. | [Copy of Newspaper Publication 7 Sep - 11th AGM on 28 September 2026 at 2:00 PM via VC/OAVM.](https://nsearchives.nseindia.com/corporate/BIOMEDICA_07092026115742_Newspaper_Publication-Bio_Medica.pdf) |
| 6 July 2026 - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 6 July 2026 - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026.](https://nsearchives.nseindia.com/corporate/BIOMEDICA_06072026161853_Regulation_74_5_-Final.pdf) |
| 4 Sep - 11th AGM on 28 Sep 2026; adopts FY26 results, reappoints Mukesh Mehta, appoints secretarial auditor, raises FPI/FII limit to 49%. | [Shareholders meeting 4 Sep - 11th AGM on 28 Sep 2026; adopts FY26 results, reappoints Mukesh Mehta, appoints secretarial auditor, raises FPI/FII limit to 49%.](https://nsearchives.nseindia.com/corporate/BIOMEDICA_04092026170142_AGM_Notice_Bio_Medica.pdf) |
| 29 Jul - Submitted newspaper clipping of standalone and consolidated audited results for year ended 31 March 2026. | [Copy of Newspaper Publication 29 Jul - Submitted newspaper clipping of standalone and consolidated audited results for year ended 31 March 2026.](https://nsearchives.nseindia.com/corporate/BIOMEDICA_29072026123919_Newspaper_Publication.pdf) |
| 29 Jul - Corporate governance report not applicable for quarter ended 30 June 2026 under SME exemption. | [Integrated Filing- Governance 29 Jul - Corporate governance report not applicable for quarter ended 30 June 2026 under SME exemption.](https://nsearchives.nseindia.com/corporate/BIOMEDICA_29072026142516_Non_Applicability_IG.pdf) |
| 28 Jul - Postal ballot seeks approval to sell 51% Vitamax stake and authorize loans, guarantees, investments, and related-party transactions. | [Shareholders meeting 28 Jul - Postal ballot seeks approval to sell 51% Vitamax stake and authorize loans, guarantees, investments, and related-party transactions.](https://nsearchives.nseindia.com/corporate/BIOMEDICA_28072026164846_Notice_of_Postal_Ballot-Final1.pdf) |
| 28 Jul - Postal ballot for 51% Vitamax sale, higher loan limits, and related-party transaction approvals. | [Shareholders meeting 28 Jul - Postal ballot for 51% Vitamax sale, higher loan limits, and related-party transaction approvals.](https://nsearchives.nseindia.com/corporate/BIOMEDICA_28072026141428_Notice_Postal_Ballot_Final.pdf) |
| 27 Jul - Board approved FY26 audited results, unmodified audit, and postal ballot for subsidiary disinvestment and related approvals. | [Outcome of Board Meeting 27 Jul - Board approved FY26 audited results, unmodified audit, and postal ballot for subsidiary disinvestment and related approvals.](https://nsearchives.nseindia.com/corporate/BIOMEDICA_27072026191343_final_results__1_.pdf) |
| 27 Aug - Shareholders approved subsidiary sale, loan/guarantee powers, Rs100 crore investments, and Rs50 crore RPTs on 27 Aug 2026. | [Shareholders meeting 27 Aug - Shareholders approved subsidiary sale, loan/guarantee powers, Rs100 crore investments, and Rs50 crore RPTs on 27 Aug 2026.](https://nsearchives.nseindia.com/corporate/BIOMEDICA_27082026175001_Scrutinizer_report_Final.pdf) |
| 24 July 2026 - Postal ballot approved MOA main objects alteration with new objects on 23 July 2026. | [Shareholders meeting 24 July 2026 - Postal ballot approved MOA main objects alteration with new objects on 23 July 2026.](https://nsearchives.nseindia.com/corporate/BIOMEDICA_24072026124809_Voting_Results_and_Scrutinizer_report.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2026 from nse](https://archives.nseindia.com/annual_reports/SME_AR_31394_BMLL_2025_2026_A_28292178_04092026165731.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:47:51.909Z.